Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 18Recruiting 3Active not recruiting 3Unknown 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Chronic-Phase 1Blast Crisis 1

Interventions

asciminib 10Cyclophosphamide 9Mycophenolic Acid 7fludarabine 5Whole-Body Irradiation 5nilotinib 4fludarabine phosphate 4Stem Cell Transplantation 4Specimen Handling 4Dasatinib 4olverembatinib 3bosutinib 3Imatinib Mesylate 3Cyclosporine 3venetoclax 2ponatinib 2blinatumomab 2X-Rays 2Thiotepa 2Tacrolimus 2Sirolimus 2Melphalan 2Magnetic Resonance Spectroscopy 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporins 2Bone Marrow Transplantation 2Blood Component Removal 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × bosutinib × Clear all
NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06297161 2026-04-14

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Pfizer

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06423911 2025-06-03

POLARIS-2

Ascentage Pharma Group Inc.

Phase 3 Recruiting
285 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡